BR112020000791A2 - métodos para detecção de discrasia de célula plasmática - Google Patents

métodos para detecção de discrasia de célula plasmática Download PDF

Info

Publication number
BR112020000791A2
BR112020000791A2 BR112020000791-9A BR112020000791A BR112020000791A2 BR 112020000791 A2 BR112020000791 A2 BR 112020000791A2 BR 112020000791 A BR112020000791 A BR 112020000791A BR 112020000791 A2 BR112020000791 A2 BR 112020000791A2
Authority
BR
Brazil
Prior art keywords
variants
expression
union
level
individual
Prior art date
Application number
BR112020000791-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark Kidd
Ignat Drozdov
Irvin Mark Modlin
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of BR112020000791A2 publication Critical patent/BR112020000791A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818Sequencing of polypeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
BR112020000791-9A 2017-07-21 2018-07-18 métodos para detecção de discrasia de célula plasmática BR112020000791A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
US62/535,419 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (1)

Publication Number Publication Date
BR112020000791A2 true BR112020000791A2 (pt) 2020-07-21

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020000791-9A BR112020000791A2 (pt) 2017-07-21 2018-07-18 métodos para detecção de discrasia de célula plasmática

Country Status (13)

Country Link
US (3) US20190025311A1 (https=)
EP (1) EP3655553B1 (https=)
JP (1) JP7223741B2 (https=)
KR (1) KR102785072B1 (https=)
CN (1) CN111194356B (https=)
AU (1) AU2018304242B2 (https=)
BR (1) BR112020000791A2 (https=)
DK (1) DK3655553T3 (https=)
ES (1) ES2916450T3 (https=)
IL (1) IL271465B2 (https=)
MX (1) MX2020000785A (https=)
PL (1) PL3655553T3 (https=)
WO (1) WO2019018540A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655553B1 (en) 2017-07-21 2022-03-23 Liquid Biopsy Research LLC Methods for detection of plasma cell dyscrasia
CN114901819A (zh) 2019-10-10 2022-08-12 液体活检研究有限责任公司 用于生物样品和rna稳定化的组合物、方法和试剂盒
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
WO2021243206A1 (en) * 2020-05-29 2021-12-02 Exosome Diagnostics, Inc. Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004378A (es) * 2001-11-07 2004-09-10 Univ Arkansas Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
JP2004313167A (ja) 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
CA2567350C (en) * 2004-05-21 2018-06-12 John D. Shaughnessy Use of gene expression profiling to predict survival in cancer patient
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
JP2012514460A (ja) * 2009-01-02 2012-06-28 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー ボルテゾミブを用いた多発性骨髄腫患者における生存率の予測
WO2011152884A2 (en) * 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) * 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma
EP3655553B1 (en) 2017-07-21 2022-03-23 Liquid Biopsy Research LLC Methods for detection of plasma cell dyscrasia

Also Published As

Publication number Publication date
WO2019018540A1 (en) 2019-01-24
AU2018304242A1 (en) 2020-01-16
US20230022417A1 (en) 2023-01-26
KR20200029528A (ko) 2020-03-18
EP3655553B1 (en) 2022-03-23
IL271465B2 (en) 2023-08-01
CN111194356B (zh) 2024-04-23
DK3655553T3 (da) 2022-06-20
MX2020000785A (es) 2020-11-06
IL271465B1 (en) 2023-04-01
CA3067730A1 (en) 2019-01-24
US20260118360A1 (en) 2026-04-30
ES2916450T3 (es) 2022-07-01
US12366575B2 (en) 2025-07-22
JP7223741B2 (ja) 2023-02-16
CN111194356A (zh) 2020-05-22
KR102785072B1 (ko) 2025-03-20
PL3655553T3 (pl) 2022-09-26
JP2020528274A (ja) 2020-09-24
AU2018304242B2 (en) 2023-04-27
US20190025311A1 (en) 2019-01-24
EP3655553A1 (en) 2020-05-27
IL271465A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
KR102114412B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
US12366575B2 (en) Chemical compositions and methods of use
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
KR20110015409A (ko) 염증성 장 질환에 대한 유전자 발현 마커
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
KR20110110031A (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
MXPA05005653A (es) Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca.
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
US12399179B2 (en) Chemical compositions and methods of use
JP2003259877A (ja) 肝線維症疾患マーカーおよびその利用
CN101778954A (zh) Egfr抑制剂治疗的预测性标记物
KR20190126812A (ko) 질환 진단용 바이오마커
CN101827948A (zh) 检测鳞状细胞癌和腺癌及其高级别癌前病变的新分子标记
CA3067730C (en) Methods for detection of plasma cell dyscrasia
HK1084696A (en) Prognostic for hematological malignancy

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]